Company Overview and News
THE stock brokerage arm of the Bank of the Philippine Islands (BPI) projects the Philippine Stock Exchange index (PSEi) to close around the 8,200 level by year-end, as investors focus on companies’ fundamentals amid rising inflation and the weakening peso.
GTCAP GTCXY SMCP1 SMGBF SMC JBFCF MPCFF PHSXY PSE SPHXF SPHZF UVRBF AYAAF PSKXF MPCIY AYAAY JBFCY UVRBY SMGBY SMPH SMC2B SMC2A SMC2D SMC2C MPI SMC2F SPHXY SMC2E JFC URC ALI
HENRY SY, Sr. remains the country’s wealthiest man for the 11th straight year in Forbes Asia’s “Philippines’ 50 Richest” list, which reflected the economy’s overall volatility as many registered shifts in wealth from 2017.
ICT JGSMY GTCAP GTCXY SVTMF NIKL SMCP1 JGS SM ICTEF SECB SMGBF SMIVY SMC ALGGY SBS AGI JGSHF GMA7 SMGBY NIKAY SMC2B SMC2A SMC2D TECH SMC2C SMC2F SYBJF SMC2E ALGGF GNWKY LTG
The benchmark Philippine Stock Exchange index closed in positive territory Thursday even as regional equities saw mixed results on lingering trade tensions between the United States and China.
ICT GTCAP GTCXY SVTMF BDOUY SM ICTEF SECB BDOUF SMIVY MPCFF PHSXY PSE SPHXF SPHZF AYAAF PSKXF MPCIY AYAAY SMPH BDO MPI SPHXY SYBJF ALI
SHARES SLUMPED on Wednesday as the local market paused for a break after rallying past the 7,800 level in previous days.
GTCAP GTCXY SMCP1 RBNTF AEV SMGBF SMC MPCFF RRETY PHSXY PSE RRHI PSKXF MPCIY SMGBY SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E BBRRF BLOOM
THE property unit of GT Capital Holdings, Inc. will be launching five more residential projects in the second half of 2018, after posting lower reservation sales in the first half due to fewer units left in its inventory.
GT Capital Holdings, Inc. looks to grow its earnings in the mid-single digits for full year 2018, amid recording flat profit for the first semester after the implementation of the Tax Reform for Acceleration and Inclusion (TRAIN) law dented auto sales.
GTCXY GTCAP MPCFF MPCIY MPI
SHARES snapped their five-day winning streak on Tuesday after investors resorted to profit taking ahead of the United States Federal Reserve’s meeting this week, even as those overseas remained predominantly buyers.
ICT GTCAP GTCXY GTMEY BDOUY ICTEF BDOUF JBFCF MPCFF PHSXY GTMEF PSE GLOPA UVRBF AYAAF DMC PSKXF MPCIY AYAAY JBFCY DMCIF UVRBY GLOPP DMCP BDO GLO MPI JFC URC DMCHY ALI
2018-07-27 bworldonline - 1
In the 21st century, disruptions abound. Companies large and small must contend with the challenges of an ever-changing corporate environment. At the same time, consumers seek out services that cater to their needs more efficiently. In this milieu of constant change, businesses must be agile and adept — at once masters in their respective fields as well as innovators advocating continuous improvement.
GTCXY GTCAP IX
A PROPERTY UNIT of GT Capital Holdings, Inc. has sealed a deal with Metro Pacific Investments Corp.’s (MPIC) logistics arm to sell its Cavite property for P1.02 billion.
GTCXY PSKXF GTCAP PX MPCFF MPCIY MPI PXMFF PHSXY PSE PXMFY
2018-07-11 bworldonline - 1
TEN Philippine companies made it to the Nikkei Asian Review’s third annual list of Asia300 Power Performers Ranking, which ranks the most powerful and valuable listed companies in Asia.
JGSMY GTCAP GTCXY JGS CEBUY JBFCF MPCFF SPHXF SPHZF CEB JGSHF UVRBF AYAAF DMC MPCIY AYAAY JBFCY DMCIF UVRBY DMCP SMPH CEBUF MPI SPHXY JFC URC DMCHY ALI
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET